Plain-English translation of NCT07444203 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
TRIDENT 2.0 is a research study that looks at kidney tissue under a microscope to understand how SGLT2 inhibitors — a class of diabetes medications — help protect kidneys in people with diabetes-related kidney disease. Researchers will use advanced imaging and testing techniques to map the damage and healing patterns in kidney tissue samples. This work may help doctors better understand which patients benefit most from this medication.
Diabetes damages kidneys in many people, and while this medication shows promise in protecting kidney function, scientists don't fully understand how it works at the tissue level. This study will provide that missing information to help develop better treatments and predict who will benefit most.
You likely qualify if…
You likely don't qualify if…
If you qualify, you won't need to visit a clinic or take new medications — this is an observational study that uses kidney tissue you may have already had removed during a past procedure. Researchers will access your stored tissue sample and review your medical records to see what medications you took and how your kidneys responded. The study team will analyze the tissue using advanced laboratory techniques to understand the effects of the medication at a microscopic level.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States